Atlas Wealth »

Provectus Biopharmaceuticals I shares owned by Atlas Wealth

Quarter-by-quarter ownership of Provectus Biopharmaceuticals I (PVCT) shares owned by Atlas Wealth from 13F filings

Historical chart of Atlas Wealth investment in Provectus Biopharmaceuticals I

Tip: Access up to 7 years of quarterly data

All positions including Provectus Biopharmaceuticals I held by Atlas Wealth consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Provectus Biopharmaceuticals I by Atlas Wealth

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.2k 27k 0.08
2023-09-30 $2.2M 27k 84.49
2023-06-30 $3.1M 27k 114.80
2023-03-31 $4.4M 27k 164.99
2022-12-31 $2.9k 27k 0.11

More positions owned by Atlas Wealth

U.s. Bancorp Pfd B Preferred Stock (USB.PH)
Bank Of America Corporation Pfd 1/1200ser2 Preferred Stock (BML.PH)
Apple Incorporated Common Stock (AAPL)
Goldman Sachs Group, Incorporated. Pfd A 1/1000 Preferred Stock (GS.PA)
Procter And Gamble Company Common Stock (PG)
Morgan Stanley Pfd A 1/1000 Preferred Stock (MS.PA)
Microsoft Corporation Common Stock (MSFT)
Goldman Sachs Group Inc Shs D 1/1000 Preferred Stock (GS.PD)
Alphabet Incorporated Cap Stk Class C Common Stock (GOOG)
Bank Of America Corporation Pfd1/1200 Sr1 Preferred Stock (BML.PG)
First Trust Rba American Industrial Renaissance Etf Exchange Traded Funds (Country Baskets/iShares) .. (AIRR)
Jpmorgan Chase & Company Common Stock (JPM)
John Hancock Multifactor Small Cap Etf Exchange Traded Funds (Country Baskets/iShares) - Domestic (JHSC)
Metlife Inc Floating Rate Non-cum Perp Pfd Floats Quarterly Preferred Stock (MET.PA)
Amazon Com Incorporated Common Stock (AMZN)

View all positions for Atlas Wealth

Top funds holding Provectus Biopharmaceuticals I

Home Federal Bank Of Tennessee
Lee, Danner & Bass
Atlas Wealth
LBMC Investment Advisors
Financial Symmetry
Huntington National Bank

View all funds holding Provectus Biopharmaceuticals I